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The in vitro incubation of human sickle cell erythrocytes (SS RBCs) with sodium
cyanate results in significant prolongation of their 'Cr intravascular survival (1,
2). This effect appears to be mediated through carbamylation of the amino terminal
valine residue in the hemoglobin S molecule which results in inhibition of erythro-
cyte sickling (3). Initial clinical studies have shown that the oral administration
of sodium cyanate to patients with homozygous sickle cell disease also increases
erythrocyte survival and leads to improvement in anemia (4, 5). Sickle cell crises,
however, continue to occur in the cyanate treated patients (5). This observation
raises serious questions regarding the effectiveness of cyanate treatment in the pre-
vention of localized intravascular sickling, and in the overall clinical management
of patients with sickle cell disease.
Pretreatment of rats with (a) ethyl palmitate (EP) which blocks the reticulo-
endothelial system and produces acute splenic necrosis, and (b) cobra venom factor
(CVF) which inhibits the third component of complement has resulted in the de-
velopment of an animal system suitable for study of the intravascular survival
of human erythrocytes (6). It now has been shown that two important similarities
exist between the behavior of SS RBCs in humans and the behavior of SS RBCs
transfused into rats which have been pretreated with EP and CVF (7). The first
is that SS RBCs have a significantly shorter 5'Cr life span than that of control RBCs.
Secondly, exposure of rats which had been breathing 100% O. to a hypoxic en-
vironment results in the rapid loss from circulation of from 30-60% of the trans-
fused human SS RBCs. These observations suggest that the rat model might be
of value in determining the effectiveness of antisickling drugs in the prevention
of accelerated SS RBC loss from circulation during hypoxia. The immediate objec-
tives of our experiments were to determine the effect of cyanate treatment of human
SS RBCs on their survival in the rat model and, more importantly, the behavior
of carbamylated human SS RBCs in th^ rat during the stress of hypoxia.
'This research was supported by U.S. Public Health Service Training Grant #HL 05316-13
and by U.S. Public Health Service Research Grant #CA I 1 106-10.
55
Copyright (C 1974, by Academic Press, mnc.
All rights of reproduction in any form reserveO.CASTRO, ORLIN AND FINCH
MATERIALS AND METHODS
The blood from 4 patients with homozygous sickle cell anemia was studied. None
of the patients had been transfused for at least 2 mo prior to this study. Their
ages were 1, 22, 23, and 33 yr. Each patient had from 87.5 to 93.4% S hemoglobin
as determined by acrylamide gel electrophoresis and hematocrit values ranging from
20 to 30%.
Four milliliters of venous blood from each patient was added to 1 ml of sterile
acid-citrate-dextrose solution and separated into 2 equal portions. Both were centri-
fuged and the supernatant plasmas were removed. The packed red cells in one
tube were made up to the original volume with a solution of sodium cyanate2 in
normal saline so that the final cyanate concentration was 50 mM. The other tube
of packed red cells was made up to volume with normal saline instead of cyanate.
Oxygen was bubbled through the red cell suspensions for a period of 3-5 min.
Sodium 5"Chromate3 (50tiCi/ml blood) was then added to each sample, and the
mixtures were incubated at 370C for 90 min with frequent swirling. The erythrocyte
suspensions were washed three times with normal saline in order to remove un-
bound chromium and cyanate. Normal saline was added to bring the final hemato-
crit to 30-33%. The degree of amino terminal valine carbamylation achieved in
the cyanated sample was 2.0 cyanate residues per mole of hemoglobin tetramer.4
Erythrocytes from 3 control individuals with A hemoglobin (AA RBCs) were
processed both with and without cyanate incubation in exactly the same manner
as was the blood from the patients with sickle cell disease.
Erythrocyte survival studies were performed in adult, male Sprague-Dawley rats
weighing between 150 to 250 g. Each animal was prepared for the transfusion
study according to a technique which has been previously described (7). Briefly,
the method involves tail vein injection of a suspension of ethyl palmitate in a dose
of 3 g/kg approximately 12-24 hr before the red cell survival study. A second
tail vein injection with 10 units of CVF was given about 30 min before the study.
The 51Cr tagged human erythrocyte suspension (1 ml/kg of packed cells) was in-
jected in the animals through the dorsal vein of the penis. Fifteen minutes later,
and at intervals of 30 min to 1 hr thereafter, 10 FAl capillary blood samples were
taken from the tip of the tail for radioassay in a well-type scintillation counter.
The radioactive counts for each animal were normalized and plotted on semilog
paper in order to determine erythrocyte half-time (T-1) survival. The radioactivity
from the first sample was defined as the 100% value. A total of 26 rats were
used for these experiments.
Each patient study usually involved simultaneous determination of SS erythrocyte
survival in 4 rats. Two animals were injected with cyanate treated SS RBCs and
the other 2 with SS RBCs that had not been treated with cyanate. One of the
2 rats injected with cyanate treated SS RBCs was left in room air during the entire
51Cr survival study while the other was placed in a hypoxic environment (10%
02) following a 2 hr period of exposure to 100% O2 as previously described (7).
The 51Cr survival of control animals, i.e., those transfused with SS RBCs not treated
with cyanate and those transfused with carbamylated and noncarbamylated AA
RBCs, was determined under the same conditions.
2 Pfaltz and Bauer, Inc., Flushing, NY.
'E. R. Squibb and Sons, New Brunswick, NJ.
'This determination was performed by Dr. Anthony Cerami.
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TABLE I
EFFECT OF CYANATE TREATMENT ON THE 51Cr SRIVTRNIXAL
CHARACTEIRISTICS OF SS RBCs TRANSFUSEI) TO RATS
Untreated SS RBC Cyaniate treated SS RBC
T-' survival % loss" T-1 survival % loss"
inl hr ill ill lIr ill
Patienit (room air) 10%o )02 (r'oomliar) 10% 02
J.G. 4.5 45 ia.5 4
S.El. 4. n iiot (lOIDe 6.0() iot (loile
B.T. 12M. 43 9.5 32
S.B. 7.7 312 17.0 33
Average 4.5 40 10.2 36
a During the first 60 mill of exposure to 10% 02 ill relation to tile 1l)oo0( radioactivity preseeit
immediately before hypoxia.
In a separate experiment, the erythrocytes from patient S.B. with sickle cell dis-
ease were labeled with radioactive cyanate: Twenty-five /ACi potassium '4C cyanate5
was added to the nonradioactive sodium cyanate and this mixture was added in
the usual proportions to the SS RBCs after removal of the plasma. The subsequent
incubation and washing steps were the same as for 51Cr labeled RBCs, except that
1.5 ml RBCs/kg rat wt were injected. Following transfusion of 11C-cyanate labeled
blood into the rats 20 ml capillary samples were taken from the animals at the
usual intervals. The capillary pipettes containing the blood samples were emptied
into counting flasks containing 0.2 ml of 30% hydrogen peroxide. Five milliliters
of Aquasol6 solubilizer was added to the flasks and 14C radioactivity counted in
a liquid scintillation counter. The '-C RBC survival characteristics were compared
to those of 5"Cr labeled noncarbamylated RBCs from the same patient.
RESULTS
The effect of in vitro cyanate treatment of SS RBCs on their survival in rats
is shown in Table 1. Carbamylation of SS RBCs resulted in considerable prolonga-
tion of erythrocyte survival for each of the 4 patients tested. The mean T-1 erythro-
cyte survival of the cyanate treated cells was more than double that of the non-
carbamylated SS RBCs. The significance level (t test on the paired samples) was
less than 0.1. The T- I survival of the cyanate treated SS RBCs was shifted into
the AA RBC T-1 survival range (7) in 2 of the 4 studies performed. The 51Cr
survival of erythrocytes from three Hb A control individuals was not prolonged
by cyanate treatment. The mean T-1 for untreated AA RBCs was 18 hr while
that for cyanate treated Hb AA RBCs was 14.6 hr.
Experiments in which the animals were placed in 10% O. following an initial
period of 100% O. administration showed no essential difference between the cya-
nate treated and untreated SS RBCs: There was rapid loss from circulation of
32-42% of the cyanate treated SS RBCs in comparison to a 32-45% loss of the
untreated SS RBCs within the first 60 min of exposure to the hypoxic environment
(Table 1). A representative example of a single experiment is shown in Fig. 1.
5 New England Nuclear, Boston, MA.
'New England Nuclear, Boston, MA.
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FIG. 1. Effects of variations in 0, concentration on the 51Cr survival of cyanate treated
and untreated (control) RBSs from a patient with sickle cell anemia. Hypoxia (10% 02)
resulted in rapid loss of SS RBCs which could not be prevented by pretreatment with
cyanate.
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FIG. 2. Comparison of the survival char-acteristics of carbamylated SS RBCs (1C cyanate
was used as a label.) and noncarbamylated "Cr labeled SS RBCs (control) from the same
patient. Exposure of the animals to hypoxia (10% 02) was associated with a similar rapid
drop in both "4C and "Cr counts.
The survival of SS RBCs labeled with 'C cyanate and "Cr tagged SS RBCs
not treated with cyanate is shown in Fig. 2. The initial portion (100% 02) of
the survival curve of noncyanated SS RBC (51Cr curve) was no different than that
of the SS RBCs which had been treated with cyanate ("IC curve). Subsequent
exposure to 10% O. for 1 hr resulted in a 31% drop in 1'C counts and a 44%
drop in 5'Cr counts. The characteristics of the 2 survival curves in room air during
the next 15 hr were similar.
DISCUSSION
The results of the carbamylated SS RBC survival studies in this rat model are
similar to those which have been reported for studies performed in human subjects
( 1, 2, 4, 5). In both species, the in vitro treatment of SS RBCs with cyanate results
in improvement of their survival to the extent that the blood T-1 values approachCARBAMYLATED SICKLE CELLS IN RATS
those for untreated AA RBCs. Since the effect of carbamylation is probably limited
to the inhibition of sickling, one can conclude that the shortened survival of SS
RBCs in the rat in room air probably relates to continuous erythrocyte sickling
in areas in the body with low oxygen concentration. This hypothesis is further
strengthened by the fact that exposure of the animals to 100% 02 during an SS
RBC transfusion study also improves SS RBC survival (7). The period of observa-
tion during which the animals were breathing 100% O. was too short (2 hr),
however, to accurately compare the effect of hyperoxygenation alone vs cyanate
alone on the survival of SS RBCs.
The degree of hemoglobin carbamylation achieved in our studies is well within
the range which has been effective in prolonging SS RBC survival in man (1, 2,
5). Partial correction of hemolytic anemia in patients with sickle cell disease
has been achieved with maintenance of a minimum of 0.3 residues of cyanate per
mole of hemoglobin (4, 5).
Our studies also indicate that the accelerated loss of a substantial proportion
of human SS RBCs from the hypoxic animal's circulation could not be prevented
by cyanate. The following explanations can be offered for the failure of cyanate
treated SS RBCs to resist the in vivo effects of hypoxia. (a) The loss of blood
radioactivity during hypoxia ("hypoxic drop") could represent selective removal
of those SS RBCs which had not been carbamylated despite incubation with cya-
nate. This explanation seems most unlikely because the survival characteristics of
SS RBCs labeled only with 14C-cyanate were almost identical to those seen with
the 51Cr labeled RBCs from the same patient. (b) The hypoxic drop could have
been the result of selective removal of carbamylated but irreversibly sickled cells.
[Deoxygenated SS RBCs can be carbamylated in the sickled state and carbamyla-
tion per se does not reverse sickling (3)]. Also this explanation does not seem
probable: The hypoxic drop can best be demonstrated immediately after a period
of time in which the animals breathed 100% 02. If the loss of radioactivity seen
during the subsequent period of hypoxia were due to loss of irreversibly sickled
cells, one would not expect that a preceding period of hyperoxygenation of the
animal would have been needed in order to demonstrate the hypoxic phenomenon.
(c) The hypoxic drop could be dependent on other factors which are not directly
influenced by HbS carbamylation. Erythrocyte age, content of hemoglobin F in
the individual cell, or changes in membrane pliability or membrane loss due to
repeated sickle-unsickle cycles may be responsible.
The foregoing considerations and our previous observations (7) strongly suggest
that in homozygous sickle cell disease there are at least two populations of erythro-
cytes in terms of their survival characteristics in the rat model. One population
of cells is exquisitely sensitive to changes inO. tension so that they accumulate
in the blood of animals breathing 100% 02 and are rapidly removed from circula-
tion following hypoxia. The second population is also abnormal since it has a short-
ened survival but differs from the first population in that hypoxia does not seem
to accelerate their removal from circulation. Cyanate appears to increase the intra-
vascular survival of both populations but does not seem to prevent the accelerated
removal of the SS RBCs most sensitive to oxygen changes during the initial period
of oxygen deprivation.
The overall interpretation of these results is guarded in terms of their extrapola-
tion to man. The rat model is extremely sensitive to sickling (preliminary studies
suggest that the survival of RBCs of patients with sickle cell trait is somewhat
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shorter than that of AA RBCs) and may actually overemphasize the response of
human SS RBCs to hypoxia. On the other hand, if an antisickling agent such as
cyanate fails to improve or prevent the accelerated loss of SS RBCs in the rat
model during hypoxia, one might seriously question the effectiveness of that agent
in other species during a comparable challenge.
The similarities between the results obtained with carbamylated human SS RBCs
in the rat model and in man provide some additional evidence for the potential
usefulness of this model in the study of sickle cell disease and the efficacy of various
therapeutic agents.
SUMMARY
The 5"Cr survival characteristics of cyanate-treated erythrocytes from four pa-
tients with sickle cell anemia were studied in rats which had been pretreated with
ethyl palmitate and a cobra venom factor. Cyanate-treated sickle cells showed sig-
nificant improvement in their survival characteristics in room air. Carbamylation,
however, did not prevent the accelerated loss of sickle cells from the rat's circula-
tion following exposure to hypoxia. In a single experiment 14C-cyanate was used
both as an erythrocyte label and carbamylating agent. The drop in 14C activity
following exposure to hypoxia was of the same magnitude as that observed with
noncarbamylated 51Cr-labeled sickle cells. These findings suggest heterogeneity for
human sickle erythrocytes in the rat model in terms of their sensitivity to variations
in oxygen concentration. Carbamylation fails to protect that population of cells
which is most sensitive to the stress of severe hypoxia. The significance of these
findings in relationship to human disease has not been defined, but the similarities
between the behavior of cyanate-treated sickle cells in humans and in the rat sug-
gest that this simple animal model may be of considerable value in the study of
sickle cell disease and its treatment.
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